Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xencor Inc (XNCR)

Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,686,566
  • Shares Outstanding, K 69,982
  • Annual Sales, $ 168,340 K
  • Annual Income, $ -126,090 K
  • EBIT $ -217 M
  • EBITDA $ -218 M
  • 60-Month Beta 0.66
  • Price/Sales 9.86
  • Price/Cash Flow N/A
  • Price/Book 2.30

Options Overview Details

View History
  • Implied Volatility 93.49% ( -1.31%)
  • Historical Volatility 25.98%
  • IV Percentile 64%
  • IV Rank 64.02%
  • IV High 130.46% on 08/30/24
  • IV Low 27.72% on 08/06/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 204
  • Open Int (30-Day) 254

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.83
  • Number of Estimates 6
  • High Estimate -0.61
  • Low Estimate -1.07
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -167.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.73 +17.90%
on 10/24/24
24.44 unch
on 11/22/24
+3.21 (+15.12%)
since 10/22/24
3-Month
16.14 +51.47%
on 09/06/24
24.44 unch
on 11/22/24
+7.77 (+46.61%)
since 08/22/24
52-Week
15.31 +59.63%
on 08/07/24
26.84 -8.94%
on 02/27/24
+5.71 (+30.49%)
since 11/22/23

Most Recent Stories

More News
Xencor: Q3 Earnings Snapshot

Xencor: Q3 Earnings Snapshot

XNCR : 24.35 (+1.04%)
Xencor: Q2 Earnings Snapshot

Xencor: Q2 Earnings Snapshot

XNCR : 24.35 (+1.04%)
Xencor: Q1 Earnings Snapshot

Xencor: Q1 Earnings Snapshot

XNCR : 24.35 (+1.04%)
Xencor: Q4 Earnings Snapshot

Xencor: Q4 Earnings Snapshot

XNCR : 24.35 (+1.04%)
5 Growth Stocks with 66% Upside Potential or More

Here's a closer look at five growth stocks that analysts expect to rally in 2024 as the Fed prepares to pivot to a more dovish policy stance.

GAMB : 12.89 (-0.85%)
SOUN : 8.30 (+18.91%)
XNCR : 24.35 (+1.04%)
RKLB : 22.97 (+2.50%)
GSAT : 1.7850 (+0.85%)
2 Growth Stocks With 35% to 150% Upside in 2024

While all eyes are on AI stocks, there are a few undervalued growth stocks that have the potential to provide investors with massive long-term returns.

ACB : 4.35 (+1.16%)
CGC : 3.95 (+2.33%)
GTBIF : 9.1000 (-2.57%)
$SPX : 5,964.40 (+0.26%)
CRLBF : 1.1450 (-0.43%)
XNCR : 24.35 (+1.04%)
2 Beaten-Down Growth Stocks With 90% or More Upside Potential in 2024

While these stocks have taken a beating this year, Wall Street believes they have major rebound potential in 2024.

XNCR : 24.35 (+1.04%)
TCNNF : 5.9500 (-2.78%)
Xencor: Q3 Earnings Snapshot

Xencor: Q3 Earnings Snapshot

XNCR : 24.35 (+1.04%)
Xencor: Q2 Earnings Snapshot

Xencor: Q2 Earnings Snapshot

XNCR : 24.35 (+1.04%)
Xencor: Q1 Earnings Snapshot

Xencor: Q1 Earnings Snapshot

XNCR : 24.35 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 25.07
2nd Resistance Point 24.64
1st Resistance Point 24.37
Last Price 24.35
1st Support Level 23.67
2nd Support Level 23.23
3rd Support Level 22.96

See More

52-Week High 26.84
Last Price 24.35
Fibonacci 61.8% 22.44
Fibonacci 50% 21.08
Fibonacci 38.2% 19.71
52-Week Low 15.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar